The aspartate-specific caspases are critical protease effectors of programmed cell death and consequently represent important targets for apoptotic intervention. Baculovirus P35 is a potent substrate inhibitor of metazoan caspases, a property that accounts for its unique effectiveness in preventing apoptosis in phylogenetically diverse organisms. Here we report the 2.2 Å resolution crystal structure of P35, the first structure of a protein inhibitor of the death caspases. The P35 monomer possesses a solvent-exposed loop that projects from the protein's main β-sheet core and positions the requisite aspartate cleavage site at the loop's apex. Distortion or destabilization of this reactive site loop by site-directed mutagenesis converted P35 to an efficient substrate which, unlike wild-type P35, failed to interact stably with the target caspase or block protease activity. Thus, cleavage alone is insufficient for caspase inhibition. These data are consistent with a new model wherein the P35 reactive site loop participates in a unique multi-step mechanism in which the spatial orientation of the loop with respect to the P35 core determines post-cleavage association and stoichiometric inhibition of target caspases.
Introduction
Apoptosis, or programmed cell death, is a multi-step, signalinduced mechanism for cellular destruction. It is a highly regulated suicide process that is crucial for normal development, tissue homeostasis and defense from foreign pathogens, including viruses (Steller, 1995; Hardwick, 1997; Jacobson et al., 1997) . Aberrant or misregulated apoptosis is associated with tumorigenesis, degenerative diseases and virus pathogenesis (Thompson, 1995) . The components of the death apparatus are well conserved and include the caspases, a family of cysteinyl proteases that are critical apoptotic effectors (Hengartner and Horvitz, 1994; Martin and Green, 1995; Fraser and Evan, 1996; Nicholson and Thornberry, 1997; Cryns and Yuan, 1998) . After proteolytic activation from their proenzyme form, these aspartatespecific proteases induce nuclear and cytoplasmic con-densation, internucleosomal DNA fragmentation, cytoskeletal rearrangements and plasma membrane blebbing, all morphological hallmarks of apoptosis. The diversity of anti-apoptotic proteins that affect either caspase activation or activity indicates that these death proteases provide a decisive control point in the commitment to apoptotic death (White, 1996; Villa et al., 1997; Cryns and Yuan, 1998) .
In a strategy to block host cell defenses and promote multiplication, viruses have evolved diverse anti-apoptotic genes that regulate the cell death machinery (Shen and Shenk, 1995; Hardwick, 1997; O'Brien, 1998) . Baculovirus p35 is of particular interest since it not only blocks virusinduced apoptosis (Clem et al., 1991) , but also functions as a general and effective suppressor of programmed cell death in diverse organisms when expressed ectopically (Rabizadeh et al., 1993; Cartier et al., 1994; Hay et al., 1994; Sugimoto et al., 1994; Beidler et al., 1995; Martinou et al., 1995; Robertson et al., 1997) . This feature has been exploited in a promising first example of anti-apoptosis therapy in which eye-specific expression of p35 prevents blindness in retinal degeneration mutants of Drosophila (Davidson and Steller, 1998) .
Accounting for its broad effectiveness as an apoptotic suppressor, protein P35 is a potent inhibitor of group I, II and III caspases (Bump et al., 1995; Xue and Horvitz, 1995; Bertin et al., 1996; Zhou et al., 1998) . Lacking sequence similarity to any known protease regulators including the serpins, this 299 residue protein is a substrate inhibitor in which cleavage at Asp87 of the caspase recognition sequence 84-DQMD↓G-88 is correlated with caspase inhibition. Asp87 is a critical residue since replacement causes loss of P35 anti-apoptotic activity and abrogates in vitro caspase inhibition (Xue and Horvitz, 1995; Bertin et al., 1996) . Upon stoichiometric inhibition of human caspase-1, the 10 and 25 kDa cleavage products of P35 remained stably associated with the inhibited caspase (Bump et al., 1995) . This finding suggested that P35 acts as an irreversible, or slowly reversible suicide inhibitor. In an alternative model, P35 may act as a competitive inhibitor if present at sufficiently high levels (Xue and Horvitz, 1995) . Thus, the mechanism by which P35 accomplishes broad specificity caspase inhibition in vivo remains unresolved.
To define the molecular mechanism by which baculovirus P35 functions as a potent substrate inhibitor of the death caspases, we have determined its three-dimensional structure. We report here the 2.2 Å resolution crystal structure of active P35 prior to caspase cleavage. The structure provides new insight into a multi-step mechanism of caspase inhibition and opens the door to novel P35 designs for use in anticaspase therapeutic approaches.
Results
Overall structure P35 crystallized with three monomers in the crystallographic asymmetric unit, designated A, B and C. The (Smith, 1995) . (B) Electrostatic molecular surface rendering of the P35 monomer demonstrating the completely solventexposed portion of the reactive site loop (generated by the program GRASP, Nicholls et al., 1991) . Surfaces are colored by electrostatic charge, with positive and negative regions in blue and red respectively. The location of Asp87 (P 1 residue) is labeled. (C) Stereo ribbon drawing of P35 monomer B. The color scheme varies through the rainbow spectrum, starting at red for the N-terminus and ending with violet at the C-terminus. The P35 reactive site loop, which is cleaved by the caspases, is the solvent-exposed loop at the top of the protein as viewed. The scissile bond is marked with an arrow. The cellulose-binding domain fold corresponds to the β-barrel subdomain at the left portion of the structure. Figures 1C, 2 , 3A and 4 were created with the program MOLSCRIPT (Kraulis, 1991). structure was determined by multiple isomorphous replacement (MIR) at 2.9 Å resolution and refined against 2.2 Å resolution synchrotron data. The P35 monomer structure consists of a novel single domain globular protein with overall dimensions of~45ϫ55ϫ40 Å. The central core of the structure consists of an eight-stranded mostly antiparallel β-sheet (Figure 1 ). Strands βB and βI run parallel in this notably flat β-sheet. Strands βA, βD, βE and βF lie below β-strands βB, βC and βG of the central β-sheet to form a seven-stranded antiparallel β-barrel with structure and topology similar to the cellulose-binding domain (see below). Helices α2 and α3 form an antiparallel helix-turn-helix motif and lie below the cellulose-binding 2032 domain. Helix α2 bends at Lys114 to allow for the tight α2-α3 turn and helix packing against the core region.
The striking feature of the P35 structure is a large loop domain (residues 60-98), designated the reactive site loop, that protrudes above the central β-sheet core. The loop begins with a single α-helix (α1) that traverses the top of the central sheet and is succeeded by the P 4 -P 1Ј residues (84-DQMD↓G-88) that represent the caspase recognition site. The caspase cleavage site, Asp87-Gly88 (P 1 and P 1Ј residues), comprises the apex of the loop, which is solvent exposed and fully accessible to the target caspase. The position of the reactive site loop is determined in part by amphipathic helix α1 that packs Fig. 2 . Stereo superposition of P35 (drawn in green) on the cellulose-binding domain from β-1,4-xylanase (drawn in red) (PDB accession code 1EXG). While no protein structure had an overall fold comparable with that of the P35 core domain, the N-terminal portion of P35 displayed structural similarities to the type II CBD (Xu et al., 1995) . The CBD superimposes onto P35 with an r.m.s. deviation of 2.8 Å for 90 equivalent α-carbons. The three CBD tryptophan residues implicated in binding cellulose are drawn with orange bonds. The corresponding residues in P35 are different.
against the β-sheet at an unusual angle that is perpendicular to the strands of the core β-sheet. The hydrophobic residues of the helix interact with the hydrophobic residues from the central β-sheet, and the hydrophilic residues of α1 are exposed to solvent. Strand βK extends past the central β-sheet and turns upward to form a β-hairpin with βL that lies adjacent to the reactive site loop. The structure predicts that Tyr260 and Trp262 of βL make hydrophobic interactions with Tyr82 of the reactive site loop to stabilize the loop. These interactions are observed in all three monomers in the asymmetric unit. The last four strands of the central β-sheet (βJ, βK, βM and βN) organize into a β-meander motif. Strands βH and βP along with helix α4 pack underneath the right hand portion of the central eight-stranded β-sheet as viewed in Figure 1 . Since the last residue observed is Lys299, the C-terminal His 6 -Tag is disordered in all three monomers.
Correlation between P35 structure and function
The biological relevance of this P35 structure is strongly supported by previous genetic analyses, including in-frame two-codon (Ala-Ser) insertional mutagenesis (Bertin et al., 1996) . Examination of the crystal structure revealed a striking correlation between mutational disruption of defined secondary structures and the loss of P35 function. For example, all insertions located within β-sheets (in10, in28, in105, in152, in197, in278 and in290) and within α-helices (in74 and in130) caused loss of function. In contrast, mutations (in145, in174, in205, in223, in240, in254 and in273) located within intervening loops that could accommodate insertions without disruption of adjacent secondary structure had no phenotypic effect. Thus, the observed pattern in which disruption of defined secondary structure caused loss of function, but insertions within intervening loops exerted little if any effect, suggests that the structure of P35 as determined here represents a biologically relevant structure of this protein.
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Cellulose-binding domain similarity The P35 structure was used as a search model to probe a three-dimensional structural database to find similar folds (Holm and Sander, 1993) . While no protein structure had an overall fold comparable with that of the P35 core domain, the N-terminal portion of P35 displayed structural similarities to the type II cellulose-binding domains (CBD) (Xu et al., 1995) . The biological significance of this intriguing structural similarity is unknown. P35 exhibits no sequence similarity to any class of cellulose-binding proteins. The CBD similarity in P35 corresponds to the seven-stranded antiparallel β-barrel made up of β-strands A-G. This barrel superimposes on the CBD of β-1,4-xylanase/glucanase from the bacterium Cellulomonas fimi with an r.m.s. deviation of 2.8 Å for 90 equivalent α-carbons, as calculated by the program LSQKAB (Kabsch, 1976) (Figure 2 ). The topology of CBD is identical to the cellulose-binding motif of P35 with the exception of strand βA. In P35, this strand is at the N-terminus, whereas in CBD the structurally equivalent strand comes from the Cterminus of the protein. Nonetheless, the directionality of all strands is identical. P35 also contains two large insertions not found in CBD. The reactive site loop, consisting of helix α1 and the solvent-exposed caspase target site, is inserted between strands βD and βE. Also, the two antiparallel helices α2 and α3 positioned below the CBD are inserted between strands βE and βF. In spite of the sequence and structural differences, P35 does have an affinity for cellulose, with a dissociation constant of 3 μM (data not shown).
Flexibility of the reactive site loop
Part of the unusual reactive site loop of P35 extends away from the main β-core and is completely solvent exposed. This reactive loop functions as the primary recognition site for the target caspases. Strict non-crystallographic symmetry (NCS), which was constrained during the early stages of structural refinement, was relaxed, resulting in a better agreement between the model and both the working and cross-validated data. This improved the electron density map to model the solvent-exposed segment of the reactive site loop (residues 84-95) and the adjacent hairpin loop between strands βK and βL (residues 252-259). All three monomers in the asymmetric unit are very similar in structure, with the largest deviations occurring at these two loop regions. The loop displacements, which culminate up to 5.7 Å at the apex of the reactive site loop, result from the three distinct crystal packing environments in the asymmetric unit ( Figure 3A) . The observed variances, along with weak electron density and high crystallographic temperature values that define these loops, indicate flexibility and/or conformational latitude amid residues in these loops ( Figure 3B ). Despite plasticity, the reactive site loop extends from the main β-core and is completely solvent exposed in all three P35 monomers ( Figure 3A ). The inherent flexibility of the loop, which includes the caspase recognition residues, may contribute to P35's broad specificity as a caspase inhibitor.
P35 interaction with caspase
A current model for P35 anti-apoptotic activity proposes that P35 inhibits caspase activity by a mechanism wherein cleavage at Asp87 leads to formation of a stable P35-caspase complex (Bump et al., 1995; Bertin et al., 1996; Zhou et al., 1998) . To examine possible P35-caspase interactions, we superimposed the main chain atoms of the P35 P 4 -P 1 cleavage residues (84-DQMD-87) with those of the tetrapeptide inhibitor DEVD-CHO bound in the active site of human caspase-3, a known target of P35 for which the structure is known (Rotonda et al., 1996; Mittl et al., 1997) . The superposition made it possible to generate a model of pre-cleaved P35 complexed with caspase-3 ( Figure 4A ). The P 4 -P 1 residues of P35 fit well within the caspase-3 active site with no obvious steric hindrances, due in part to the sharp turn at the scissile bond between Asp87 and Gly88 ( Figure 4B ). A feature of this P35-caspase-3 modeled pre-cleavage complex is the limited number of interactions and contacts between P35 and caspase-3 due to the outstretched solventexposed reactive site loop, which is observed with all three P35 monomers in the asymmetric unit. The model does propose potential hydrophobic interactions, adjacent to the active site, between the P35 βK-βL hairpin loop and a loop at residue 381 in caspase-3. However, this caspase loop is significantly different between the major subfamilies of caspases based on sequence alignments and structural analysis of human caspase-1 and caspase-3 2035 (Rotonda et al., 1996; Mittl et al., 1997) . Caspase-3 contains a 10 residue insert at a position equivalent to residue 381 in caspase-1. This caspase loop contributes to the S 4 binding pocket that defines the P 4 residue specificity. In the modeled complex with P35, this loop contains many aromatic residues that lie in close proximity to aromatic residues in the βK-βL loop of P35 ( Figure  4B ). Trp262 of P35 is 4.3 and 3.9 Å away from Phe381B and Phe381D, respectively in caspase-3 (the caspase-3 numbering scheme is that used in PDB file 1PAU which was used to facilitate easier comparisons with caspase-1). A small post-cleavage conformational change in either the caspase-3 381 insertion loop or the P35 βK-βL hairpin loop could promote hydrophobic interactions between these loops. Nonetheless, it is unlikely that these potential interactions contribute to the high affinity of P35 for caspase (K i ϭ 100 pM) (Zhou et al., 1998) since P35 effectively inhibits caspases lacking this loop. The potency of P35 as an inhibitor of group I, II and III caspases (Zhou et al., 1998) argues that P35 inhibition involves a structural or mechanistic feature shared among the caspases and a stabilization of interactions between P35 and the target caspases.
Requirement for cleavage site Asp87 for caspase association
To define the molecular determinants of stable interaction between P35 and caspase, we tested the contribution of the reactive site loop and its critical P 1 cleavage residue Asp87, both of which make initial contact with the caspase. When mixed with human caspase-3 overproduced in insect cells, the wild-type P35-His 6 crystallized here was cleaved to generate the signature 10 and 25 kDa fragments ( Figure  5A and B). In contrast, caspase-3 failed to cleave D87A-mutated P35-His 6 (lane 5) in which Asp87 was replaced with alanine, a loss-of-function mutation (Xue and Horvitz, 1995; Bertin et al., 1996) . Both caspase-3 subunits (p17 Increasing amounts of purified wild-type (wt) P35-His 6 (5-50 μg) or P 1 (D87A)-mutated P35-His 6 (50 μg) were mixed with caspase-3-containing insect cell extracts. P35-His 6 and associated proteins subsequently were isolated by metal (Ni 2ϩ ) affinity chromatography and analyzed by SDS-PAGE. Shown are a stained gel (A), and immunoblots using antiserum to P35 (B) and the p17 (C) and p12 (D) subunits of caspase-3. Full-length P35 and its N-terminal ( *Ј ) and C-terminal ( * ) cleavage products are shown on the top. and p12) associated with wild-type P35-His 6 ( Figure 5C and D, lanes 1-4), as indicated by their co-purification during metal (Ni 2ϩ ) affinity chromatography. The extent of caspase-3 interaction paralleled the amount of input P35-His 6 and the level of P35 cleavage. Moreover, both N-and C-terminal P35 cleavage products co-purified with the complex (Figure 5B) , consistent with the hypothesis that their retention contributes to caspase inhibition (Bump et al., 1995) . However, no stable association between caspase-3 subunits and D87A-mutated P35-His 6 was detected ( Figure 5C and D, lane 5). Under these conditions, caspase-3 did not associate with the Ni 2ϩ resin in the absence of wild-type P35-His 6 (data not shown). Due to the direct correlation between Asp87-dependent cleavage and stable interaction with caspase-3, we concluded that Asp87 is required for complex formation by providing the scissile bond for P35 cleavage or by promoting recognition and initial binding of P35 to the target caspase.
Role of the P35 reactive site loop in caspase inhibition
To investigate these mechanistic possibilities, we determined the effect of distorting the P35 reactive site loop without altering Asp87. Previous mutational studies indicated that two-codon Ala-Ser insertions within the reactive Increasing amounts of the indicated P35 were mixed with purified caspase-3 (0.2 pmol). After 30 min, residual protease activity was measured by using the tetrapeptide substrate DEVD-AMC in fluorometric assays. Values of a representative experiment are shown as the averages of duplicate determinations expressed as a percentage of total protease activity. (C) Association of P35 and caspase-3. After incubation of the indicated P35-His 6 (25 μg) with caspase-3-containing insect cell extracts, proteins were isolated by metal (Ni 2ϩ ) affinity chromatography and analyzed as described in the legend to Figure 5 . A stained gel (top panel) and immunoblots using antiserum to the p17 and p12 subunits of caspase-3, respectively (bottom panels), are shown. No proteins were detected in the absence of P35-His 6 (lane 4). site loop caused P35 loss of function (Bertin et al., 1996) . In contrast, charged-to-alanine substitutions of residues comprising the solvent-exposed portion of the reactive site loop (R64, D65, R66, K70, D72, E73, H90, D91, K97, D98 and E99), other than the P 4 -P 1 cleavage residues, had no effect. Thus, the size and orientation of the reactive site loop contribute to caspase inhibition more than surface charge. Since the spatial configuration of the loop is determined in part by the interaction of helix α1 with the β-core (Figure 1 ), we disrupted α1 by replacing the central residue Val71 with proline, a known helix breaker. This single residue substitution caused P35 loss of function since V71P-mutated P35 failed to prevent baculovirusinduced apoptosis (data not shown). Nonetheless, as demonstrated by in vitro protease assays, V71P-mutated P35-His 6 is an efficient caspase substrate ( Figure 6A ). In the presence of purified human caspase-3, an 8-fold molar excess of V71P-mutated P35-His 6 was cleaved to completion. In contrast, wild-type P35-His 6 stoichiometrically inhibited caspase-3 as indicated by limited P35 cleavage. Moreover, V71P-mutated P35-His 6 failed to inhibit caspase-3 in dose-dependent assays that used the tetrapeptide DEVD-AMC as substrate ( Figure 6B ). Compared with wild-type P35-His 6 , V71P-mutated P35-His 6 was as ineffective in inhibiting caspase-3 activity as cleavage-deficient D87A-mutated P35-His 6 . The loss of caspase inhibition correlated with the failure of V71P-mutated P35-His 6 to associate stably with caspase-3 ( Figure 6C ). Wild-type (lane 1), but not V71P-mutated P35-His 6 (lane 2), co-purified with p17 and p12 subunits by Ni 2ϩ affinity chromatography. Nonetheless, the larger P35 cleavage fragment co-purified with the smaller V71P-containing fragment (r), which exhibited an altered mobility (lane 2). The association of both cleavage fragments suggested that the overall structure of V71P-mutated P35 was not disrupted even upon caspase cleavage. We concluded that distortion of the reactive site loop converts P35 from a substrate inhibitor to an efficient but noninhibitory substrate. These data provide the first evidence that P35 residues outside the P 4 -P 1 recognition site participate in caspase inhibition.
Discussion
The 2.2 Å resolution structure of active P35 prior to caspase cleavage revealed a novel reactive site loop that projects from the main β-sheet core of the protein in an orientation fully accessible to a target caspase (Figure 1) . The solvent-exposed configuration of the flexible loop is determined in part by its interactions with the main framework of P35, which includes a CBD of unknown biological function (Figure 2) . Our structural and biochemical data indicate a critical role for P35's reactive site loop in a multi-step mechanism for stoichiometric caspase inhibition. Whereas the P 1 residue (Asp87) is required for P35 anti-apoptotic activity, cleavage here is not sufficient for stable association with the target caspase or its inhibition. Thus, an additional inhibitory event(s) is required. In light of the limited pre-cleavage contacts modeled between P35 and human caspase-3 (Figure 4) , a cleavageinduced conformational change that stabilizes the interaction of P35 with the target caspase probably accounts for the observed high-affinity inhibition. Charged-to-alanine substitutions of residues comprising the solvent-exposed portions of the reactive site loop, including transverse helix α1, had little effect on P35 function (Bertin et al., 1996) . However, distortion of helix α1 by the substitution V71P eliminated stable association and caspase inhibition without affecting cleavage by the target caspase ( Figure  6 ). These findings suggested that the orientation of the reactive site loop with respect to the main body of P35 is critical for post-cleavage caspase interactions. P35's potency as an inhibitor of all known caspase groups suggests that a structural or mechanistic feature shared among the diverse caspases contributes to such interactions. Further studies are required to define the molecular contacts between P35 and protease in the complex.
Despite the lack of sequence similarity between P35 and the serpins (serine protease inhibitors), the P35 reactive site loop may be functionally analogous to the reactive center of the serpins. Protease inhibition by the serpins 2037 involves cleavage-induced conformational changes (Carrell et al., 1994; Schreuder et al., 1994) that promote formation of a detergent-stable complex (reviewed in Whisstock et al., 1998) . To date, the molecular interactions between serpin and target protease in the inhibited complex remain unresolved. Although it is not yet known whether pre-cleaved P35 inhibits caspase activity, the functional analogy between serpin and P35 reactive sites suggests that a vulnerable loop may be a common mechanistic feature of cleavage-dependent protease inhibitors, irrespective of protease class or specificity. Nonetheless, it is noteworthy that the mechanism of P35-mediated suicide inhibition is distinct from that of the serpins. Although quite stable, the inhibited P35-caspase complex is detergent labile. Moreover, P35 exhibits a universal specificity for caspases, but excludes non-caspase proteases (Bump et al., 1995; Xue and Horvitz, 1995; Bertin et al., 1996; Ahmad et al., 1997; Zhou et al., 1998) . Thus, P35 is distinguished from the cowpox virus serpin CrmA, which is a highly selective caspase inhibitor (Pickup et al., 1986; Zhou et al., 1998) .
The three-dimensional structure of P35 offers new insights into mechanisms of protease inhibition, specifically that of the caspases. The rational design of new P35-based inhibitors with the potential for increased selectivity among classes of caspases is now possible. Such discrimination between death proteases would be a requirement for strategies of in vivo caspase inactivation when used in therapeutic approaches (Jacobson, 1998) for treatment of inflammatory and apoptosis-associated diseases.
Materials and methods
Protein expression and crystallization P35 from the baculovirus Autographa californica nucleopolyhedrovirus (AcMNPV) strain L1 was cloned into an Escherichia coli pET vector expression system (Novagen, Madison, WI) resulting in expression of protein with a C-terminal His-Tag extension (P35-His 6 ). Cloning, expression and protein purification details are described elsewhere (Bertin et al., 1996) . Recombinant His-tagged P35 protein inhibited apoptosis in a similar fashion to wild-type (Bertin et al., 1996) . P35-His 6 protein was crystallized by hanging-drop vapor diffusion and by microbatch at 4°C in 1.5-2.0 M Na ϩ /K ϩ PO 4 , 100 mM NaCl, 1% ethylene glycol, pH 7.0. The final protein concentration was 5-10 mg/ml. The crystals grew to the size of 0.7ϫ0.2ϫ0.2 mm in 4 weeks and belong to the orthorhombic space group C222 1 with unit cell parameters of a ϭ 114.6 Å, b ϭ 130.1 Å, c ϭ 181.1 Å. A V M coefficient was calculated to be 2.41 Å 3 /Da (49% solvent) assuming two P35 homodimers per asymmetric unit (ASU) (Matthews, 1968) . Dynamic light scattering data suggest that P35 forms homodimers in solution (data not shown). However, initial low-resolution electron density maps phased by multiple isomorphous derivatives produced three regions of protein density. Three P35 monomers/ASU results in a V M of 3.21 Å 3 /Da and a solvent content of 62% by volume.
Crystals were transferred to 1.8 M Na ϩ /K ϩ PO 4 , 200 mM NaCl, 30% ethylene glycol and frozen to -170°C for data collection. Native and derivative data were collected on a Siemens Hi-Star and MSC Raxis-IV mounted on Rigaku rotating anode generators. Hi-Star data were processed with XDS (Kabsch, 1988) and scaled with ROTAVATA/ AGROVATA (CCP4, 1994) . Raxis-IV data were processed with DENZO and scaled with SCALEPACK (Otwinowski and Minor, 1997) . A 2.2 Å resolution native data set was collected on Beamline 7-1 at SSRL and processed with DENZO and SCALEPACK.
Phase determination
All heavy atoms soaks were conducted at 4°C in 1.8 M Na ϩ /K ϩ PO 4 , 100 mM NaCl, 1% ethylene glycol, pH 7.0. Heavy atom positions were determined by inspection of difference Patterson maps and difference Fourier maps. The heavy atom positions were refined and MIR phases calculated using the program PHASES (Furey and Swaminathan, 1997) . Phasing statistics are listed in Table I . The MIR pases were refined by 3-fold molecular averaging and solvent flattening using the RAVE software package (Kleywegt and Jones, 1994) . The preliminary NCS rotation matrices were determined by rotation of the initial skeletonized solvent-flattened MIR electron density map. After 15 rounds of molecular averaging and solvent flattening at 2.9 Å resolution, the averaging R-factor dropped to 21.5% with a correlation coefficient of 0.907.
Model building and refinement
The 3-fold averaged electron density map was readily interpretable and a single monomer was built into the density with aid of the molecular graphics program O (Jones et al., 1991) . Residues corresponding to the solvent-exposed portion of the reactive site loop (84-95) were disordered in the original averaged map. After initial model building, the complete asymmetric unit was generated by rotating and translating the monomer built in the averaged map. The structure was refined with non-crystallographic constraints using TNT (Tronrud et al., 1987) . After the first round of refinement, the conventional R-factor dropped to 31.5% for 95% of the recorded data between 30 and 2.9 Å resolution (working data set). The new electron density map allowed the tracing of additional residues in the reactive site loop. At this stage, the model was refined against synchrotron data, slowly extending the resolution with each round to a final resolution of 2.2 Å. The working and test data sets maintained the same lower resolution reflections upon extension. After several iterative rounds of refinement followed by manual re-building, the non-crystallographic refinement constraints were relaxed, which resulted in a drop of 1.1% in the R free value for 5% of all recorded data. The model was then subjected to subsequent rounds of simulated annealing with the program CNS (Brünger et al., 1998) , applying the maximum likelihood as a refinement target. The working and test data sets were identical to TNT refinement. The final conventional R-factor is 19.6% and the R free value is 26.0% for 95 and 5% of all recorded data, respectively (Brünger, 1992) . None of the 892 residues in the asymmetric unit plot in the disallowed region of the Ramachandran plot, and 98.7% of the residues lie in the most favored or additionally allowed regions as defined by the program PROCHECK (Laskowski et al., 1993) .
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P35-caspase assays
For caspase association assays, purified wild-type or mutated P35-His 6 was mixed with clarified, freeze-thaw extracts of~3ϫ10 6 Spodoptera frugiperda (Sf21) cells inoculated 48 h previously with a baculovirus vector expressing the human caspase-3 gene (Fernandes-Alnemri et al., 1994) . After 30 min, the reactions were diluted with binding buffer (20 mM Tris pH 7.9, 0.5 M NaCl, 5 mM imidazole) and subjected to metal affinity chromatography by using Ni 2ϩ -conjugated agarose beads. Bound proteins were eluted with binding buffer containing 1 M imidazole and analyzed by SDS-PAGE and staining with colloidal Coomassie G250 or immunoblotting with polyclonal rabbit antisera to P35, or p17 and p12 subunits of caspase-3. Immunoblots were developed by using goat anti-rabbit immunoglobulin G (Pierce) conjugated to alkaline phosphatase. D87A-mutated P35 was described previously (Bertin et al., 1996) . Overlap extension PCR using complementary primers 5Ј-AGAAT-AAAATCAAAACCGGATGAACAATTTGAT-3Ј and 5Ј-ATCAAATT-GTTCATCCGGTTTTGATTTTATTCT-3Ј were used to generate pET-22B containing p35 for production of V71P-mutated P35-His 6 . The codon substitution was verified by nucleotide sequencing. For cleavage assays, wild-type or mutated P35-His 6 was mixed with purified human caspase-3 in 100 mM HEPES (pH 7.5), 0.1% CHAPS and 10% sucrose. C-terminal His 6 -tagged caspase-3 was purified by overexpression in E.coli and metal affinity chromatography. Reaction products were analyzed by electrophoresis on 10-20% polyacrylamide gradient gels followed by staining. For protease inhibition assays, P35-His 6 was mixed with purified caspase-3 (200 fmol) using reaction conditions described elsewhere (Bertin et al., 1996) . After 30 min, the tetrapeptide substrate Ac-DEVD-AMC (Peptides International) was added to 10 μM and the accumulation of fluorescent product (excitation, 360 nm; emission, 465 nm) was monitored by using a Biolumin 960 microplate reader (Molecular Dynamics). Rates of product formation were obtained over the first 10% of substrate depletion, and percentage protease activity is reported as the ratio of the calculated rates in the presence and absence of P35-His 6 .
